The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis
Open accessAbstract
The objective of this study was to investigate the interaction between levels of BAFF (B-cell activation factor of the tumour necrosis factor [TNF] family) and APRIL (a proliferation-inducing ligand) and B-cell frequencies in patients with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) treated with the B-cell-depleting agent rituximab. Ten patients with SLE were treated with rituximab in combination with cyclophosphamide and corticosteroids. They were followed longitudinally up to 6 months after B-cell repopulation. Nine patients with RA, resistant or intolerant to anti-TNF therapy, treated with rituximab plus methotrexate were investigated up to 6 months after treatment. The B-cell frequency was determined by flow cytometry, and serum levels of BAFF and APRIL were measured by enzyme-linked immunosorbent assays. BAFF levels rose significantly during B-cell depletion in both patient groups, and in patients with SLE the BAFF levels declined close to pre-treatment levels upon B-cell repopulation. Patients with SLE had normal levels of APRIL at baseline, and during depletion there was a significant decrease. In contrast, patients with RA had APRIL levels 10-fold higher than normal, which did not change during depletion. At baseline, correlations between levels of B cells and APRIL, and DAS28 (disease activity score using 28 joint counts) and BAFF were observed in patients with RA. In summary, increased BAFF levels were observed during absence of circulating B cells in our SLE and RA patient cohorts. In spite of the limited number of patients, our data suggest that BAFF and APRIL are differentially regulated in different autoimmune diseases and, in addition, differently affected by rituximab treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jonsson, M. V., Szodoray, P., Jellestad, S., Jonsson, R., & Skarstein, K. (2005) · Journal of Clinical Immunology · doi:10.1007/s10875-005-4091-5 · Cited by 229
Cited by
Petri, M., Stohl, W., Chatham, W., McCune, W. J., Chevrier, M., Ryel, J., Recta, V., Zhong, J., & Freimuth, W. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23678 · Cited by 428
Rituximab in systemic lupus erythematosusA systematic review of off-label use in 188 cases
Ramos-Casals, M., Soto, M., Cuadrado, M., & Khamashta, M. (2009) · Lupus · doi:10.1177/0961203309106174 · Cited by 304
Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab
Pellkofer, H. L., Krumbholz, M., Berthele, A., Hemmer, B., Gerdes, L. A., Havla, J., Bittner, R., Canis, M., Meinl, E., Hohlfeld, R., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e3182152881 · Cited by 296
B cells and antibodies in multiple sclerosis pathogenesis and therapy
Krumbholz, M., Derfuss, T., Hohlfeld, R., & Meinl, E. (2012) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.203 · Cited by 267
Furie, R., Stohl, W., Ginzler, E. M., Becker, M., Mishra, N., Chatham, W., Merrill, J. T., Weinstein, A., McCune, W. J., Zhong, J., et al. (2008) · Arthritis Research & Therapy · doi:10.1186/ar2506 · Cited by 263
Lunde, S., Kristoffersen, E. K., Sapkota, D., Risa, K., Dahl, O., Bruland, O., Mella, O., & Fluge, Ø. (2016) · PLoS ONE · doi:10.1371/journal.pone.0161226 · Cited by 22
Metadata
- Authors
- Vallerskog, T., Heimbürger, M., Gunnarsson, I., Zhou, W., Wahren-Herlenius, M., Trollmo, C., & Malmström, V.
- Venue
- Arthritis Research & Therapy
- Published
- 2006-11-08
- Volume
- 8
- Issue
- 6
- Pages
- R167-R167
- ISSN
- 1478-6354 (ISSN-L)
- OpenAlex
- W1576993812
- Cited by
- 190
- References
- 1
- FWCI
- 10.96
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.